June 17, 2016
Cambridge, MA

A Note from the CEO

It has been an exciting and eventful year for Solid Biosciences. Since our last update in 2015, Solid has grown significantly, adding team members, entering into new collaborations and moving into larger offices that include our own laboratory. Through all of this growth, our mission and resolve to find treatments, and one day a cure, for Duchenne muscular dystrophy remains as strong as ever.

In November, we gained significant momentum for our Solid GT gene therapy program with a $42.5 million Series B financing led by Perceptive Advisors, a prominent New York-based healthcare investment group, and Biogen, a leading biotechnology company. In parallel, we have built a world-class company, bringing in a team of experts in the various aspects of drug development.  We also put together one of the finest Scientific Advisory Boards in the industry, with the expertise and experience to guide us to success. 

With our strong financial foundation and through the dedication of our team and network of collaborators, we hope to begin clinical trials for our lead micro-dystrophin gene therapy candidate in 2017. In addition, we continue to build a robust pipeline of candidates that address other important factors – symptoms and physical mobility – thus implementing our 360-degree approach to tackling Duchenne muscular dystrophy. By encompassing all of the right pieces and constantly evaluating additional and newer platforms, modalities and technologies, we are doing our best to develop and advance meaningful interventions that benefit the entire DMD community.  

My wife Annie and I understand firsthand the needs of families affected by Duchenne muscular dystrophy in their everyday lives. Each of our programs is designed specifically to help every patient overcome the unique obstacles of this terrible disease.

Many of you have already contributed to these efforts, for which we are truly grateful. It is your feedback, bravery and drive that keep our team focused every day, and our commitment to you is that we will not waver until we get this done.

We will be providing regular updates on our progress as part of our commitment to open and transparent communication. In the meantime, I encourage you to visit our new website to see our latest news and find out more about our progress.

Yours,

Ilan Ganot

Solid’s Founder & CEO

Related news

Sep20

Synpromics Ltd, the leader in gene control, today announces a new research partnership with Solid Biosciences, LLC. 

Jul27

New data from the SGT-001 preclinical program was published today in Molecular Therapy – Methods and Clinical Development

Jun07
  • Jennifer Ziolkowski, CPA, joins as Chief Financial Officer.
  • Carl Morris, Ph.D., promoted to Chief Scientific Officer.
  • Joel Schneider, Ph.D., promoted to Chief Technology Officer, Head of Exploratory R&D.
Mar30

Company to Use Proceeds to Advance Programs for Duchenne Muscular Dystrophy.

Mar14

Solid Biosciences is proud to join the global Rare Disease community to recognize Rare Disease Day 2017.

Jan30

As we move into 2017, I want to reflect on our journey since founding Solid three years ago and to outline what we hope to accomplish in the coming year.

Oct14

It has been an exciting and emotional time for our Duchenne muscular dystrophy (DMD) community.

Sep20

Solid Biosciences congratulates Sarepta on the U.S. approval of the first therapy for Duchenne muscular dystrophy.

Sep08

Solid Biosciences joined the Jett Foundation and other members of the local Cambridge, MA community to observe World Duchenne Awareness Day.

Jun13

Grants from the charities Duchenne Now, Save Our Sons and Fight DMD will support important work in furthering Solid’s gene therapy and disease modifying therapy programs.

Pages

More information about Solid?

Please subscribe to receive our latest news